GlassScriptPhysician profile
Geoffrey You
NPI 1508201609
$8,053.58
in general payments reported to CMS, 2019-2025
31 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $706 · 2021: $1,219 · 2022: $1,296 · 2023: $1,553 · 2024: $1,413 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522 · Education: $77.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.14 |
| Education | $77.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,901.91 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $751.77 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $537.28 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.11 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $346.80 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Ironwood Pharmaceuticals, INC | $337.43 | 2020-2024 | Linzess |
| Pfizer INC. | $331.81 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $269.40 | 2024-2025 | Voquezna |
| Genzyme Corporation | $245.60 | 2022-2025 | |
| Madrigal Pharmaceuticals | $240.19 | 2024-2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $221.25 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $198.01 | 2020-2024 | Dificid |
| Aimmune Therapeutics, INC. | $186.56 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $170.46 | 2021-2023 | |
| Novo Nordisk INC | $170.23 | 2025 | Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $144.75 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $127.13 | 2021-2023 | Ocaliva |
| Ardelyx, INC. | $125.75 | 2022-2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $76.89 | 2024-2025 | Iqirvo, Bylvay |
| Qol Medical, LLC | $59.87 | 2021-2024 | Sucraid |
| Lilly USA, LLC | $54.32 | 2023-2024 | Omvoh |
| Alfasigma USA, INC. | $47.15 | 2020 | |
| Amgen INC. | $22.13 | 2023 | Amjevita |
| Fresenius Kabi USA, LLC | $20.89 | 2023 | Idacio |
| Mauna Kea Technologies, INC. | $19.96 | 2021 | |
| Daiichi Sankyo INC. | $19.54 | 2019 | |
| Celltrion USA INC. | $15.71 | 2024 | Zymfentra |
| Allergan, INC. | $15.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.98 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $14.54 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $12.16 | 2023 | Dat Closure Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey You listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.